### NCAC-SOT and CFSAN Joint Fall 2023 Symposium

**Abstract Guidelines**

<table>
<thead>
<tr>
<th>Include a title, author names and affiliations. (No character limit.)</th>
<th>No Tables, Figures, or Chemical Structures</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Abstract body must be ≤500 words</strong></td>
<td>Write in paragraphs without headers</td>
</tr>
<tr>
<td><strong>Indicate if the presenter is an undergraduate, graduate or postdoc student to be considered for the abstract awards.</strong></td>
<td>All presenters agree to having their abstract presented in the symposium program.</td>
</tr>
<tr>
<td>All nonstandard acronyms defined.</td>
<td>All presenters agree to accept assigned speaking date and time.</td>
</tr>
</tbody>
</table>

For acceptance, abstracts describing the results of experimental studies must contain the following:

- A statement of the rationale and scope of the study presented
- A brief description of the experimental procedures
- The data that resulted from the study
- The principal conclusion(s) based on interpretation of the results

Additionally, authors should consider the following when developing the abstract:

- Test compounds utilized in the study should be identified in the abstract.
- For “big data” studies, it can be challenging to describe results of within 500 words. Instead, include specific examples of findings to meet the requirement for description of data.
- All animal experimentation must be carried out in accordance with the Society of Toxicology’s [Guiding Principles in the Use of Animals in Toxicology](#).
- Abstracts with human testing require that IRB protocol has been followed and approval obtained.

In the case of studies that do not describe laboratory or field experiments, such as reports on educational, ethics, legal, or social initiatives, authors should:

- Describe the research or assessment approach instead of experimental procedures.
- Summarize the study’s results or findings explicitly.
- Clearly articulate the implications for stakeholders.

In addition, abstracts describing new initiatives or science policy in the regulatory community must clearly describe the impact on the practice of toxicology and/or risk assessment. Care should be taken to clearly distinguish between statements based on facts versus opinions. Regarding literature reviews: simple overviews or unstructured assessments of a topic, without novel advances in either approach or interpretation of a topic that leads to new conclusions, are discouraged. However, systematic reviews and/or advances in systematic review methods are acceptable abstract submissions.